Deletion of the steroid 21-hydroxylase and complement C4 genes in congenital adrenal hyperplasia

G RUMSBY*, M C CARROLL†, R R PORTER†, D B GRANT§, AND M HJELM*

From the Department of Clinical Biochemistry* and Growth and Development§, Institute of Child Health/Hospitals for Sick Children, Great Ormond Street, London WC1N 3JH; †the Department of Pediatrics, The Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA; and †the Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU.

SUMMARY DNA was analysed from 20 patients with congenital adrenal hyperplasia due to cytochrome P-450 steroid 21-hydroxylase deficiency. Using probes recognising sequences in both the 21-hydroxylase gene and the adjacent fourth component of complement (C4), one patient was found to have a homozygous deletion of DNA which encompassed the C4B and 21-hydroxylase B genes. Evidence is presented for this deletion arising by recombination between homologous regions of 21-hydroxylase A and B. Seven patients appeared to be heterozygous for the same deletion, but no detectable alteration in the 21-hydroxylase gene could be demonstrated in others.

Congenital adrenal hyperplasia (CAH) is an inborn error of cortisol biosynthesis. The most common form (some 95% of cases) arises from an inability to convert 17-hydroxyprogesterone to 11-deoxycortisol, a step controlled by a steroid 21-hydroxylase enzyme (EC 1.14.99.10). It is of autosomal recessive inheritance with an incidence ranging from 1 in 5000 to 1 in 15 000 in Europe and the United States, that is, of the same order of magnitude as phenylketonuria. This has led to the development of neonatal screening programmes in some regions of the United Kingdom, a recent neonatal study in Scotland finding an incidence of 1 in 18 000.1

There are four recognised clinical forms of 21-hydroxylase deficiency: salt losing, simple virilising, late onset, and cryptic. Their presentation has been reviewed by New and Levine.2 It has been known for some time that there is a close genetic linkage between the salt losing and simple virilising forms and the human leucocyte antigen (HLA) genes.3 Kohn et al4 and Levine et al5 have shown that this is also true of the late onset and cryptic forms. It has been proposed4 that these variants represent combinations of ‘severe’ and ‘mild’ alleles for 21-hydroxylase deficiency.

In recent months, the genes coding for 21-hydroxylase have been located on the short arm of chromosome 6 within the class III major histocompatibility region coding for the complement components C2, factor B, and C4 (fig 1).6 7 Two 21-hydroxylase genes (21A and B) exist, only one of which is thought to be active.7 They are located at the 3' ends of the genes for the fourth component of complement (C4).6 7

2 Dr R R Porter has died since this work was started.

Accepted for publication 6 February 1986.

204
In this study we have analysed DNA from a number of patients presenting in the neonatal period with 21-hydroxylase deficiency, in an attempt to determine whether any particular restriction fragment length polymorphism or deletion can be found to be associated with the clinical phenotype.

**Patients**

All patients presented in the neonatal period with ambiguous genitalia with (18) or without (two) salt losing crises. CAH due to 21-hydroxylase deficiency was diagnosed by grossly raised 17-hydroxyprogesterone levels before treatment.

**Methods**

Genomic DNA was isolated from peripheral blood leucocytes by the method of Bell et al.\(^8\) Samples of 10 µg were digested with restriction endonucleases according to manufacturer's instructions (Pharmacia Ltd). Digests were separated on 0.75 % agarose gels, treated according to Wahl et al.,\(^9\) and blotted onto nitrocellulose.\(^10\)

Probes were labelled with \(^{32}\)P by nick translation.\(^11\) Hybridisation was carried out at 65°C in a solution containing 5 x SSC (1 x SSC is 0.15 mol/l sodium chloride, 0.015 mol/l sodium citrate, pH 7.0), 10 % w/v dextran sulphate, 0.02 % w/v ficoll, 0.02 %

---

**FIG 2**  Simplified restriction map of the C4 and 21-hydroxylase genes in a control subject and patient A showing the proposed limits of the deletion.
w/v bovine serum albumin, 0·02 % w/v polyvinylpyrollidine, 0·1 % w/v sodium dodecyl sulphate (SDS), and 100 μg/ml denatured herring sperm DNA. Blots were washed for 4 × 5 minutes in 3 × SSC, 0·1 % w/v SDS at room temperature, followed by 4 × 15 minutes in 1 × SSC, 0·1 % SDS at 65°C. After drying they were exposed to Fuji 100-RX x-ray film at −70°C with an intensifying screen.

The probes used were as follows: probe K, unique sequences derived from a BglII digest of a 4 kilobase pair (kb) KpnI genomic fragment isolated from cosmid Cos 1E3 and containing the 5’ end of the 21A gene; probe F, cDNA extending from the 3’ non-coding region to within approximately 400 bp from the 5’ end of the coding region; and probe A, 0·5 kb BamHI/KpnI fragment from the full length C4 cDNA insert of pAT-A (fig 2).

Results

Owing to the proximity of the 21-hydroxylase and C4 genes, restriction fragments can be generated which contain parts of both genes (fig 2) and can therefore be detected by both C4 (A) and 21-hydroxylase (K) specific probes. By using a combination of three probes, a clear deletion of DNA in the 21-hydroxylase region was found in one of the 20 samples analysed. This patient (patient A) (HLA type A9,32 B44,13 Cw4 DR1,7) with the salt losing form of CAH was found to have a deletion of a 12 kb BglII fragment following hybridisation with probe K, the control showing two bands of 12 and 11 kb (data not shown). The 12 kb band is part of the 5’ C4B region and includes the 21-hydroxylase A gene (fig 2). The presence of a deletion was supported by probe A which, in the control, hybridised to the other end of this fragment (fig 2). No other smaller fragments were detected with either probe K or A following BglII digestion, suggesting that the entire fragment was missing.

However, following hybridisation of a TaqI digest with probe K, a single band of 3·2 kb was seen, whereas the control contained two fragments of equal intensity at 3·2 and 3·7 kb (fig 3, lanes 1 and 2).
The 3·2 and 3·7 kb bands are derived from the 21A and 21B genes respectively. Thus, absence of the 3·7 kb fragment is consistent with a deletion of 21B and not of 21A. Further evidence for deletion of the 21B gene was found following hybridisation of probe K to DNA digested with two other enzymes, KpnI and PvuII. In the former case two bands of 4 and 3 kb were seen in the control. As probe K is derived from a 4 kb KpnI genomic sequence in the 5' region of the 21A gene, and is therefore a marker for 21A, the 3 kb fragment presumably arises from 21B. The latter is deleted in patient A (fig 3, lanes 3 and 4). Similarly, with the PvuII enzyme two bands, 2·0 and 1·8 kb, were found in the control but only the 2·0 kb in this patient (fig 3, lanes 5 and 6). These results also show that although the 21-hydroxylase genes share sufficient homology to hybridise to the same probe, they can be differentiated by restriction fragment length polymorphisms.

The extent of the deletion in patient A was found to include the C4B gene as all specific restriction markers for the C4B gene, for example, 1·7 kb BglII and 3·5 kb BamHI fragments usually detected with probe F, were absent (data not shown). This is consistent with the finding of a homozygous null allele at the C4B locus on protein typing.

Fig 2 shows a simplified restriction map of the C4-21 hydroxylase gene region in a healthy subject and patient A. Our results are consistent with a deletion that extends from the 3' end of the 21A gene to a homologous region at the 3' end of the 21B gene including C4B, as indicated in fig 3. This could have arisen by recombination between two misaligned chromosomes, as depicted in fig 4.

Double digests with EcoRI and BglII were carried out on DNA from all patients. This digest has the advantage of yielding fragments which cover the entire 21A and 21B gene regions but, being smaller, can be more easily resolved than those produced by BglII alone. In the control sample, four bands of 10, 8, 2·4, and 2·0 kb were present (fig 5, lane 1), the 10 and 8 kb arising from the 3' ends of 21A and 21B respectively. The 2·4 and 2·0 kb bands are from the 5' ends of the gene, but as yet it is not clear which represents the 21A and B gene. However, as patient A showed a deletion of both the 10 and 2·4 kb bands (fig 5, lane 2), it would be reasonable to assume that the 2·4 kb fragment is part of the 21-hydroxylase B gene. Seven other patients (table, patients B to H) were heterozygous for a deletion of the 10 and 2·4 kb bands, as judged from the intensity of hybridisation and also by comparison with that of an obligate heterozygote (the father of patient A, fig 5, lane 3). They were also heterozygous for the PvuII and KpnI polymorphisms, from which it can be inferred that they share the same deletion as patient A on one chromosome. There appeared to be no correlation between the sizes of the bands, and also by comparison with that of an obligate heterozygote (the father of patient A, fig 5, lane 3). They were also heterozygous for the PvuII and KpnI polymorphisms, from which it can be inferred that they share the same deletion as patient A on one chromosome. There appeared to be no correlation

---

**Fig 4** Model describing unequal crossover between two homologous chromosomes (I and II) leading to duplication of C4B-21B on one chromosome (III) and deletion of C4B-21B on the other (IV).

**Fig 5** BglII/EcoRI double digest of DNA from a normal control (lane 1), patient A (lane 2), and an obligate heterozygote (lane 3). Fragment sizes (kb) determined by inclusion of molecular size markers in the gel.
between the HLA-B type, the presence of this deletion, and the clinical phenotype as is shown in the table.

No further deletions or additional fragments were found in any other samples using probe K.

Discussion

In common with a number of other inborn errors of metabolism, such as phenylketonuria and β thalas-

saemia, it is now evident that a number of different mutations will give rise to the clinical phenotype of
gonadal adrenal hyperplasia.

The two 21-hydroxylase genes appear to share a high degree of homology and will hybridise to the same DNA probe. It is probable that they arose by duplication as proposed for the adjacent C4 genes. However, they can be distinguished by a number of restriction fragment length polymorphisms as shown here and by others.

Using these markers we have found one patient with a homozygous deletion of a large fragment of DNA which includes the C4B and 21-hydroxylase B genes. This may have arisen by an unequal crossover event during meiosis which would lead to one chromosome having a duplication of the C4B-21B locus (fig 4, III) while the other would be left with only the C4A-21A locus (fig 4, IV), making the recipient of the latter a carrier for 21-hydroxylase deficiency. Large deletions in this region have been reported previously for three different haplotypes, although in these cases leading to a loss of the C4B and 21-hydroxylase A genes which were not associated with CAH. Recombination in this region appears to be a fairly common occurrence.

A strong association has been described for the different forms of CAH with various HLA-B haplo-
types: the salt losing form with HLA-B47, simple virilising with Bw51/5, and late onset and cryptic forms with HLA-B14. Linkage is to be expected in view of the proximity of 21-hydroxylase and HLA genes on chromosome 6. The B47 haplotype also has a deletion of the 21B gene, but the extent of the deletion has not been described. Although this haplotype is associated with a null allele at the C4B locus on protein typing, Carroll et al have shown that not all null alleles can be attributed to deletions of DNA. There were no HLA-B47 types among the 18 salt losing patients studied here, the most common HLA types found being B44, B14, and B7. Only one subject with HLA-B type B44, B13 was found to have a deletion of 21-hydroxylase B on both chromosomes. In those patients apparently hetero-

zygous for this deletion, no gross abnormality could be demonstrated in the other 21-hydroxylase B gene. In such cases, sequencing of the remaining B gene may identify point mutations, that is, changes in a single nucleotide which could otherwise only be detected if they altered a restriction enzyme site.

In conclusion, this work indicates that the clinical phenotype of 21-hydroxylase deficiency is due to a heterogeneous collection of defects and only in occasional instances arises from a substantial deletion of DNA.

We wish to thank Professor J R Batchelor and the Department of Immunology, Royal Postgraduate Medical School, Hammersmith Hospital for the HLA and C4 protein typing data, and Dr W M Hague, Cobbold Laboratories, Middlesex Hospital for supplying some of the patient samples.

References


4. Grant, M Hjelm, G Rumsby, M C Carroll, R R Porter, D B.
Deletion of the steroid 21-hydroxylase and complement C4 genes in congenital adrenal hyperplasia


Carroll MC. Campbell RD, Porter RR. The mapping of 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. Proc Natl Acad Sci USA 1985;82:521-5.

White PC, Grossberger D, Onufer BJ, New MI, Dupont B, Strominger JI. Two genes steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci USA 1985;82:1089-93.


Wahl GM, Stern M, Stark GR. Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl paper and rapid hybridisation by using dextran sulphate. Proc Natl Acad Sci USA 1979;76:3683-7.


Correspondence and requests for reprints to Dr G Rumsby, Department of Clinical Biochemistry, Institute of Child Health, 30 Guilford Street, London WC1N 1EH.